Showing 1971-1980 of 5063 results for "".
- DERMAFLASH® Brings Benefits of Dermaplaning Homehttps://practicaldermatology.com/news/dermaflash-brings-benefits-of-dermaplaning-home/2458738/DERMAFLASH™ is the newest addition to the DIY beauty device market. Designed specifically for women, the noninvasive exfoliation device is based on the principles of dermaplaning. DERMAFLASH uses sonic vibration to sweep away dead skin cells, vellus and even coarser
- FDA Approves Two New indications for Cosentyxhttps://practicaldermatology.com/news/fda-approves-tow-new-indications-for-cosentyx/2458745/The FDA has approved Cosentyx® (secukinumab, Novartis) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases tha
- Psoriasis Treatment Update: Rx Enstilar® Is Herehttps://practicaldermatology.com/news/psoriasis-treatment-update-rx-enstilaris-is-here/2458747/Enstilar®, the recently approved plaque psoriasis foam, is now available in pharmacies by prescription. Manufactured by LEO Pharma, Inc., Enstilar
- Concern About Zika Virus in US Set to Escalatehttps://practicaldermatology.com/news/concern-about-zika-virus-in-us-set-to-escalate/2458751/U.S dermatologists may start to receive calls from patients who are concerned about infection with Zika virus – particularly pregnant ones. Zika is now spreading rapidly across Latin America and the Caribbean. So far, one case has been identified in Houston, but the possibility
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- ASDS Goes Triple Platinum in MarCom Awardshttps://practicaldermatology.com/news/asds-goes-triple-platinum-in-marcom-awards/2458778/The American Society for Dermatologic Surgery and American Society for Dermatologic Surgery Association were recognized with 14 awards – including three Platinums – in the 2015 MarCom Awards competition. The MarCom Awards is an international competition administered and judged by the
- Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of Commercial Operationshttps://practicaldermatology.com/news/aclaris-therapeutics-inc-appoints-brett-fair-as-senior-vice-president-of-commercial-operations/2458784/Aclaris Therapeutics, Inc. has appointed Brett Fair as Senior Vice President of Commercial Operations. Mr. Fair brings more than 18 years of pharmaceutical commercialization and business
- Safe, Inexpensive Chemical Found to Reverse Symptoms of Progeria in Human Cellshttps://practicaldermatology.com/news/safe-inexpensive-chemical-found-to-reverse-symptoms-of-progeria-in-human-cells/2458787/New work from the University of Maryland suggests that a common, inexpensive and safe chemical called methylene blue could be used to treat progeria—and possibly the symptoms of normal aging as well. A new study shows for the first time that small doses of methylene blue can almost complete
- Data: Acne Sufferers Lack Understanding About Use of Antibiotics to Treat Acne and Potential Resistancehttps://practicaldermatology.com/news/data-acne-sufferers-lack-understanding-about-use-of-antibiotics-to-treat-acne-and-potential-resistance/2458797/A recent survey sponsored by Galderma Laboratories, L.P., inclusive of 809 acne sufferers (ages 17-40 years) and 210 parents of acne sufferers (child, aged 9-17 years), found that despite the risk of antibiotic resistance and potential side effects:
- Asian Acne Board and Galderma Join Forces to Improve Understanding and Management of Acnehttps://practicaldermatology.com/news/asian-acne-board-and-galderma-join-forces-to-improve-understanding-and-management-of-acne/2458799/The Asian Acne Board (AAB) and Galderma are inviting candidates to apply for a research grant of $10,000 to contribute to the improvement of best practices in the management of acne. The AAB research grant with the unrestricted support of Galderma is focused on advancing the understa